NCT07404553

A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 126 (estimated)
• Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	SHR-1918 Injection	SHR-1918 injection.
DRUG	SHR-1918 Injection Placebo	SHR-1918 injection placebo.

Timeline

• Start date: 2026-03-01
• Primary completion: 2028-07-01
• Completion: 2028-08-01
• First posted: 2026-02-11
• Last updated: 2026-02-11

Locations

1 site across 1 country: China